This is a survival comparator chart of various treatments of patients with newly diagnosed GBM.
UCLA's patient survival curve has a thick tail meaning a larger proportion of their patients have better long-term survival prospects. The beginning of their curve is similar to Stupp's curve (standard of care).
Optune, a medical device, has the strongest survival curve other than the 4 to 5 year time period where UCLA is stronger.
The treatments on the chart all have unique inclusion/exclusion trial criteria so it’s not quite comparing apples to apples but it still can be used as a guide of what we can expect. I adjusted UCLA's curve by moving it all back 3 months to simulate measuring survival from the beginning of treatment rather than beginning of diagnosis.